RadioClash
RadioClash Inc.
A revolutionary new treatment for cancer of the liver, pancreas, and bones. Effective, more affordable, faster recovery, minimally invasive.
radioclash.co · Houston, TX
Funding event
The round itself, as filedInferred stagePre-seed
Sold of offered$100K of $3.5M
Filed2026-11-03
Days since filing10
- Exemption claimed
- Rule 506(b)
- First-ever Form D
- No
- Date of first sale
- 2026-10-16
Investors
No investors named: Form D does not list them
Officers on the filing
Names and roles as filed; addresses are never stored- Yang QiaoExecutive Officer · Director
- Duane BesterExecutive Officer · Director
- Damir LjubojaExecutive Officer · Director
- Ashok GowdaDirector
Health flags
Three flags, each with the raw inputs behind it · as of 2026-11-13UndersubscribedNot flagged$100K of $3.5M sold0.9 months since first sale
Prior raiseNot flaggedRaised $100K against a prior $807K$807K prior raise, filed 2024-11-08
AmendedNot flaggedNo amendmentNo D/A on file
Open roles
On the employer's own careers page · checked 2026-11-100
Pre-posting windowNot enough dataShown once this sector and stage have 20 observed lags from filing to first posting.
No open roles foundWe read careers pages daily.
Also raised in Health & bio
Same sector, 28 days to 2026-11-15OrcosaSeries A · $6.0M of $11.5M · Ewing, NJQuietChronicleBioPre-seed · $250K of $1.0M · Menlo Park, CAQuiet
103 rounds in Health & bio in the 28 days to 2026-11-12, against 122 in the 28 days before.